Lesuwin Tablet contains Levosulpiride 25 mg, a selective dopamine D2 receptor antagonist primarily used for the treatment of gastrointestinal motility disorders and certain psychiatric conditions. Levosulpiride acts by modulating dopaminergic transmission in the central nervous system and gastrointestinal tract, thereby enhancing gastric emptying and improving symptoms such as nausea, vomiting, bloating, and abdominal discomfort associated with functional dyspepsia and gastroparesis. Additionally, it exhibits prokinetic properties that facilitate coordinated gastrointestinal motility without significantly affecting gastric acid secretion. Lesuwin is also indicated in the management of psychiatric disorders including depression and schizophrenia, where it helps alleviate symptoms by restoring dopaminergic balance. The recommended dosage and duration of therapy should be individualized based on the patient’s clinical condition and response to treatment. Common adverse effects may include drowsiness, dizziness, and extrapyramidal symptoms, which are generally mild and reversible upon discontinuation. Caution is advised in patients with a history of hypersensitivity to sulpiride derivatives, renal or hepatic impairment, and in those receiving concomitant medications that may interact with dopaminergic pathways. Lesuwin Tablet should be used under medical supervision to ensure optimal therapeutic outcomes and minimize potential risks.